Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Open Access
- 2 August 2013
- journal article
- case report
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 171
Abstract
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.Keywords
This publication has 17 references indexed in Scilit:
- Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched StudyAnnals of Surgical Oncology, 2013
- Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case ReportJournal of Clinical Oncology, 2011
- Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resectionLiver International, 2011
- Liver Resection after Downstaging Hepatocellular Carcinoma with SorafenibInternational Journal of Hepatology, 2011
- Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantationLiver Transplantation, 2010
- Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantationLiver Transplantation, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- Prognostic prediction and treatment strategy in hepatocellular carcinomaHepatology, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001